Apollo Hospitals Enterprises Ltd (AHEL) has long been a stalwart, providing a spectrum of services from hospitals to diagnostics and pharmacies in the complex landscape of healthcare enterprises. However, the recent Q2FY24 performance has raised eyebrows, revealing both strengths and challenges within the organization.
Q2FY24 Performance Breakdown
1) Hospital Segment Resilience
– AHEL reported a commendable 12 per cent YoY growth in hospital business revenue. It was attributed to an enhanced surgical mix and favourable pricing strategies.
– Despite the revenue surge, the EBITDA margin experienced a 30 basis point decline due to strategic investments in new hospitals and amplified marketing expenditure.
2) Apollo Health and Lifestyle Ltd (AHLL)
– AHLL, encompassing diagnostics and retail health, showcased an overall growth of approximately 11 per cent YoY in Q2.
– Core revenues for diagnostics witnessed a robust 17 per cent YoY growth. However, adding 655 collection centres impacted profitability, resulting in a 16 per cent YoY decline in EBITDA.
3) Health Co – Balancing Act
– The Health Co segment, comprising pharmacies and the Apollo 24/7 digital platform, reported a 16 per cent YoY revenue boost.
– Despite Apollo 24/7’s impressive 147 per cent YoY growth in Gross Merchandise Value (GMV), elevated operating costs and ESOP expenses posed challenges, leading to compromised margins.
Outlook and Strategic Initiatives
1) Healthcare Business Expansion
– AHEL’s strategic expansion plan for FY25-FY27 involves acquiring a partially built hospital in Kolkata and signing a binding agreement for a new hospital in Pune. These initiatives are poised to be pivotal in driving future growth.
2) Apollo 24/7 – A Double-Edged Sword
– Despite its rapid growth, Apollo 24/7 remains a pain point, with persistent cash burn in Q2FY24. Management aims for a cost reduction of Rs 20-25 crore in FY24, eyeing breakeven by the end of FY25.
– Offline pharmacy vertical growth is steady, but the online platform’s revenue/GMV ratio dipped to 32 per cent in Q2FY24, raising concerns.
3) Diagnostics Centers – Poised for Growth
– AHEL’s diagnostic centres are experiencing a surge in average per-day footfall. However, higher costs associated with network expansion suggest a timeline before operating leverage leads to margin expansion.
Valuation and Prudent Caution
– AHEL’s stock, currently trading at 21x EV/EBITDA for FY25e, presents an interesting valuation. It stands at a discount to its large-cap peers, yet caution is advised.
– The company’s diversified presence across hospitals, pharmacies, and diagnostics offers potential, but substantial improvements are crucial before considering it a robust investment opportunity.
Summary
While Apollo Hospitals Enterprises Ltd’s Q2FY24 performance portrays resilience in specific segments and a strategic vision for expansion, challenges in Apollo 24/7 and diagnostic profitability necessitate careful monitoring. Investors are urged to exercise prudence, waiting for crucial improvements and milestones before considering AHEL as a strong contender in the healthcare investment landscape.
Disclaimer: We do not endorse or encourage you to take trades or investment decisions based upon our posts/research, all of your trading and investment activities are your own and should be taken through consultation with reputed financial advisors. The analysis posted on this website has been created by involving multiple mediums which are present over the Internet.